stockportfolio.pro
Stocks / TXG vs VCYT
TXG vs VCYT
10x Genomics, Inc. and Veracyte, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| 10x Genomics, Inc. (TXG) | Veracyte, Inc. (VCYT) | |
|---|---|---|
| Market cap | $3.7B | $3.9B |
| Revenue (latest FY) | $642.82M | $517.14M |
| Net income (latest FY) | $-43.54M | $66.35M |
| Revenue growth (5y CAGR) | 16.6% | 34.5% |
| Net margin | -6.8% | 12.8% |
| Return on equity | -5.5% | 5.1% |
| P/E ratio | — | 44.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open TXG — free Open VCYT — freeFrequently asked questions
Which is bigger, TXG or VCYT?
Veracyte, Inc. is larger by market capitalization — $3.9B versus $3.7B.
Which grows faster, TXG or VCYT?
Over the last five fiscal years, Veracyte, Inc. grew revenue faster — 34.5%/yr versus 16.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.